Boston Scientific Corporation (NYSE:BSX) spent a flat session last Friday, ending the session with a meager loss of 0.45%. It was the fourth consecutive session in the narrow range of $17-$18 and the stock still keeps the hopes of further rally alive.
Boston Scientific Corporation (NYSE:BSX) announced the first quarter earnings result last Tuesday and the stock may have been digesting that before deciding the next course of direction. The higher than expected negative impact of the currency fluctuations and the rising litigation costs led to a significant loss for the company. The company reported a loss of $1 million, a decline of 100% on a y-o-y basis against the profit of $0.10 per share or $133 million reported in the same quarter in the previous year.
Still the result didn’t look that much bad to the market due to the 5% rise seen in the EPS, on a y-o-y basis, which was reported at $0.21 per share, after excluding items like amortization, acquisition and divesture related charges and pension termination costs. This was perfectly in line with the street expectation of $0.21. The EPS was $0.2 in the same quarter last year.
A small decline was seen in the revenue which came at $1.77 billion, reflecting a drop of 0.34% y-o-y but it was lower than the consensus of $1.8 billion. The major impact was due to the currency fluctuations, which if discounted shows an increase of 6% y-o-y on a constant currency basis.
Technically, the stock stands at a very important juncture as it trades very close to the channel boundary which has been providing it major support over the last few months. A break of the channel would signal a severe weakness of the uptrend but if the bulls can protect it, we can expect the stock to reach $20 levels.
